Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post-hoc analysis of the TULIP-1 and TULIP-2 trials.
Ian N BruceRonald F van VollenhovenEric F MorandRichard A FurieSusan ManziWilliam B WhiteGabriel AbreuRaj TummalaPublished in: Rheumatology (Oxford, England) (2022)
clinicaltrials.gov Identifier: NCT02446912 and NCT02446899.
Keyphrases